Barclays Sticks to Their Sell Rating for Zimmer Biomet Holdings (ZBH)

In a report released on November 3, Matt Miksic from Barclays maintained a Sell rating on Zimmer Biomet Holdings (ZBHResearch Report), with a price target of $105.00. The company’s shares closed yesterday at $104.85.

According to TipRanks, Miksic is a 5-star analyst with an average return of 11.2% and a 64.93% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Abbott Labs, Edwards Lifesciences, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $121.22.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $140.55 and a one-year low of $100.17. Currently, Zimmer Biomet Holdings has an average volume of 1.04M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.

Read More on ZBH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More